| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A recombinant human KRT14 fragment (within amino acids 350-472) was used as the immunogen for the KRT14 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
KRT14 Antibody / Keratin 14 / Cytokeratin 14 is an antibody targeting KRT14. Host: Rabbit. Monoclonal. Clone: KRT14/8691R. Format: Purified. Applications: IHC-P.
Key elements and design rationale
- Target: KRT14.
- Immunogen: A recombinant human KRT14 fragment (within amino acids 350-472) was used as the immunogen for the KRT14 antibody..
- Species reactivity: Human.
- Localization: Cytoplasm.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
Cytokeratin 14 is a member of the type I keratin family of intermediate filament proteins.
Common research applications
- IHC: tissue distribution assessment; interpret with matched controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
